patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_852642 | REC_0010101 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11 | 63 | female | 0 | 12 | 5.5 | 5 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.366590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179504 | REC_0010102 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.8 | 69 | female | 1 | 7 | 6.4 | 7 | sotorasib 960 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:59.366941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730816 | REC_0010103 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.6 | 71 | male | 2 | 5 | 4.9 | 1 | osimertinib 80 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:59.367200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615989 | REC_0010104 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 10 | 76 | female | 2 | 21 | 4.9 | 4 | entrectinib 600 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:35:59.367440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586769 | REC_0010105 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 17 | 73 | female | 3 | 22 | 5.9 | 2 | osimertinib 80 mg daily | 22.9 | false | MSI-H | 2026-03-15T05:35:59.367695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287508 | REC_0010106 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 1.9 | 70 | female | 2 | 25 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:59.367955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855589 | REC_0010107 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.8 | 74 | female | 2 | 6 | 4.8 | 3 | alectinib 600 mg BID | 17.3 | false | MSI-H | 2026-03-15T05:35:59.368278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742147 | REC_0010108 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.7 | 76 | female | 2 | 9 | 4.4 | 3 | osimertinib 80 mg daily | 15.7 | true | MSI-H | 2026-03-15T05:35:59.368583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571072 | REC_0010109 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 18 | 12.3 | 68 | female | 1 | 4 | 3.7 | 1 | pembrolizumab 200 mg q3w | 22.5 | true | MSS | 2026-03-15T05:35:59.368910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521329 | REC_0010110 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.2 | 55 | female | 1 | 11 | 4.3 | 8 | sotorasib 960 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:59.369279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337811 | REC_0010111 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.7 | 70 | female | 1 | 30 | 3.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:59.369636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115498 | REC_0010112 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.8 | 82 | female | 3 | 43 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.8 | false | MSS | 2026-03-15T05:35:59.369955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713140 | REC_0010113 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10 | 70 | female | 1 | 14 | 4.2 | 5 | osimertinib 80 mg daily | 5.3 | false | MSS | 2026-03-15T05:35:59.370279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959795 | REC_0010114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.8 | 71 | female | 1 | 16 | 6.2 | 1 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:59.370637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750804 | REC_0010115 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.1 | 72 | female | 2 | 21 | 6.8 | 4 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:59.371164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420919 | REC_0010116 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 14.9 | 70 | female | 3 | 22 | 6.7 | 0 | entrectinib 600 mg daily | 57.9 | false | MSI-H | 2026-03-15T05:35:59.371527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780467 | REC_0010117 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.2 | 59 | female | 1 | 12 | 4.5 | 5 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:35:59.371878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739824 | REC_0010118 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 2.2 | 81 | female | 2 | 52 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:35:59.372260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136637 | REC_0010119 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 17.5 | 78 | female | 1 | 20 | 5.2 | 2 | sotorasib 960 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:59.372609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197021 | REC_0010120 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.1 | 45 | female | 0 | 55 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:59.372922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547979 | REC_0010121 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.6 | 79 | female | 0 | 17 | 5.5 | 1 | alectinib 600 mg BID | 19.4 | true | MSS | 2026-03-15T05:35:59.373239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201652 | REC_0010122 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 12.3 | 65 | male | 0 | 11 | 5.5 | 0 | osimertinib 80 mg daily | 56.9 | false | MSI-H | 2026-03-15T05:35:59.373561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732781 | REC_0010123 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 7.6 | 64 | male | 0 | 14 | 4.9 | 1 | sotorasib 960 mg daily | 17.5 | true | MSS | 2026-03-15T05:35:59.373856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619004 | REC_0010124 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 13.8 | 64 | male | 0 | 6 | 5.3 | 1 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.374125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290092 | REC_0010125 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.8 | 54 | male | 0 | 22 | 3.6 | 7 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:59.374392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879624 | REC_0010126 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.6 | 69 | male | 1 | 16 | 3.5 | 8 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:59.374660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406616 | REC_0010127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.6 | 68 | female | 0 | 47 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:59.374927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347352 | REC_0010128 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.5 | 66 | female | 1 | 15 | 7.5 | 2 | pembrolizumab 200 mg q3w | 5.9 | false | MSS | 2026-03-15T05:35:59.375318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785433 | REC_0010129 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 7.2 | 63 | female | 1 | 17 | 5.8 | 2 | osimertinib 80 mg daily | 19.6 | false | MSS | 2026-03-15T05:35:59.375610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239985 | REC_0010130 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.6 | 71 | female | 1 | 59 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:59.375901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103097 | REC_0010131 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.7 | 63 | male | 1 | 15 | 5.8 | 2 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:59.376228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453977 | REC_0010132 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 11.6 | 78 | female | 1 | 16 | 6.5 | 7 | osimertinib 80 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:59.376492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529495 | REC_0010133 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 6.8 | 74 | female | 0 | 17 | 3.4 | 6 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.376739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386557 | REC_0010134 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 19.3 | 76 | female | 1 | 19 | 6.2 | 0 | alectinib 600 mg BID | 55.3 | true | MSS | 2026-03-15T05:35:59.376990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145703 | REC_0010135 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.6 | 74 | female | 1 | 10 | 7.5 | 6 | alectinib 600 mg BID | 15.7 | true | MSI-H | 2026-03-15T05:35:59.377249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838087 | REC_0010136 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 8.7 | 77 | female | 3 | 11 | 4.3 | 5 | pembrolizumab 200 mg q3w | 5.9 | true | MSS | 2026-03-15T05:35:59.377499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425419 | REC_0010137 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.9 | 66 | female | 1 | 20 | 6.6 | 1 | sotorasib 960 mg daily | 28.4 | false | MSS | 2026-03-15T05:35:59.377749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119979 | REC_0010138 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 15.8 | 67 | female | 1 | 19 | 4.3 | 1 | alectinib 600 mg BID | 23 | false | MSI-H | 2026-03-15T05:35:59.378003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657146 | REC_0010139 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 17.2 | 52 | male | 0 | 17 | 4.2 | 6 | osimertinib 80 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:59.378256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453102 | REC_0010140 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.2 | 66 | female | 1 | 14 | 4.2 | 8 | sotorasib 960 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:59.378511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831521 | REC_0010141 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.6 | 74 | male | 0 | 50 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:59.378889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605585 | REC_0010142 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 16.8 | 72 | female | 0 | 19 | 3.4 | 2 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:59.379170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905703 | REC_0010143 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.6 | 62 | male | 0 | 60 | 7.1 | 1 | pembrolizumab 200 mg q3w | 31.2 | false | MSS | 2026-03-15T05:35:59.379467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684244 | REC_0010144 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13.1 | 71 | male | 1 | 25 | 5.7 | 6 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:59.379759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868459 | REC_0010145 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.2 | 56 | male | 1 | 14 | 7.4 | 6 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.380136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430169 | REC_0010146 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.4 | 61 | male | 1 | 17 | 8.3 | 1 | alectinib 600 mg BID | 7.6 | true | MSI-H | 2026-03-15T05:35:59.380472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219417 | REC_0010147 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.9 | 69 | female | 1 | 25 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:59.380842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593203 | REC_0010148 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.6 | 69 | female | 0 | 15 | 6.3 | 5 | sotorasib 960 mg daily | 8 | true | MSI-H | 2026-03-15T05:35:59.381171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654476 | REC_0010149 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 17 | 13.1 | 70 | female | 2 | 10 | 5.8 | 0 | osimertinib 80 mg daily | 46.4 | true | MSI-H | 2026-03-15T05:35:59.381454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372334 | REC_0010150 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 4.9 | 66 | female | 0 | 18 | 6.1 | 7 | sotorasib 960 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.381726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531826 | REC_0010151 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.7 | 59 | male | 0 | 16 | 8.2 | 5 | osimertinib 80 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:35:59.381987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901182 | REC_0010152 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.4 | 67 | female | 1 | 7 | 6 | 3 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:59.382238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664996 | REC_0010153 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.8 | 80 | female | 2 | 42 | 5.8 | 5 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:35:59.382484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361391 | REC_0010154 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 30 | 12.3 | 74 | male | 1 | 3 | 5.4 | 0 | entrectinib 600 mg daily | 32.8 | true | MSS | 2026-03-15T05:35:59.382856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509076 | REC_0010155 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 15.8 | 67 | female | 1 | 18 | 4.8 | 1 | pembrolizumab 200 mg q3w | 15.5 | false | MSI-H | 2026-03-15T05:35:59.383121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476797 | REC_0010156 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.3 | 75 | female | 1 | 33 | 2.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.6 | false | MSS | 2026-03-15T05:35:59.383374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370674 | REC_0010157 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.2 | 82 | female | 2 | 18 | 5.9 | 5 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:59.383633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776422 | REC_0010158 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 7.3 | 76 | female | 0 | 5 | 3.8 | 4 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:35:59.383893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103705 | REC_0010159 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14 | 57 | female | 0 | 13 | 4.9 | 5 | entrectinib 600 mg daily | 4.4 | true | MSS | 2026-03-15T05:35:59.384208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940271 | REC_0010160 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8 | 64 | male | 1 | 19 | 3.6 | 8 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.384483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869541 | REC_0010161 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 9.2 | 83 | female | 2 | 14 | 5.7 | 0 | osimertinib 80 mg daily | 23.5 | true | MSS | 2026-03-15T05:35:59.384757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643731 | REC_0010162 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.4 | 72 | female | 1 | 7 | 5.4 | 4 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:59.385038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735675 | REC_0010163 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.6 | 67 | female | 0 | 10 | 5 | 2 | alectinib 600 mg BID | 30.8 | true | MSS | 2026-03-15T05:35:59.385330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173934 | REC_0010164 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 8.5 | 70 | female | 1 | 14 | 6.4 | 5 | sotorasib 960 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:59.385601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743986 | REC_0010165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.7 | 69 | female | 0 | 46 | 6.5 | 7 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:35:59.385859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738213 | REC_0010166 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 6.9 | 59 | female | 0 | 16 | 5.9 | 2 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.386114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879195 | REC_0010167 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.3 | 70 | female | 1 | 24 | 4.5 | 5 | sotorasib 960 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:59.386504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417508 | REC_0010168 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 3.5 | 72 | female | 2 | 16 | 5.4 | 1 | pembrolizumab 200 mg q3w | 15.7 | false | MSS | 2026-03-15T05:35:59.386805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848187 | REC_0010169 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.8 | 59 | male | 1 | 15 | 5.7 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.387114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120132 | REC_0010170 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.1 | 75 | female | 2 | 91 | 4.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.387395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670718 | REC_0010171 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 9.7 | 70 | male | 3 | 8 | 5.4 | 1 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.387663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121483 | REC_0010172 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.1 | 64 | female | 0 | 17 | 5.8 | 7 | entrectinib 600 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:59.387913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841090 | REC_0010173 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.8 | 70 | male | 1 | 4 | 3.4 | 3 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:35:59.388220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489455 | REC_0010174 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 13.3 | 78 | female | 2 | 19 | 2.7 | 1 | pembrolizumab 200 mg q3w | 21.9 | false | MSS | 2026-03-15T05:35:59.388479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711900 | REC_0010175 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 18.4 | 65 | male | 0 | 15 | 4.9 | 4 | osimertinib 80 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:59.388730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368667 | REC_0010176 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 11.1 | 66 | female | 1 | 22 | 6.4 | 4 | pembrolizumab 200 mg q3w | 5.7 | false | MSI-H | 2026-03-15T05:35:59.388978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759909 | REC_0010177 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.6 | 65 | male | 0 | 12 | 4 | 2 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.389233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156999 | REC_0010178 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 13.5 | 59 | male | 0 | 12 | 5.4 | 1 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:59.389494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339271 | REC_0010179 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.3 | 59 | female | 0 | 8 | 5 | 5 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:59.389770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645936 | REC_0010180 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.4 | 63 | male | 1 | 17 | 6.1 | 9 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:59.390166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121655 | REC_0010181 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 13.3 | 50 | female | 0 | 21 | 5.3 | 2 | entrectinib 600 mg daily | 24.2 | false | MSS | 2026-03-15T05:35:59.390448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488913 | REC_0010182 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 7.7 | 57 | female | 0 | 15 | 5 | 9 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.390706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214972 | REC_0010183 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.6 | 78 | female | 2 | 22 | 4.3 | 6 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.390959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175510 | REC_0010184 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.8 | 62 | male | 0 | 21 | 4 | 6 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.391213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491270 | REC_0010185 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.2 | 65 | male | 1 | 6 | 4.7 | 5 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:59.391468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378357 | REC_0010186 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.2 | 73 | male | 2 | 13 | 5.9 | 5 | sotorasib 960 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:59.391723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474040 | REC_0010187 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.4 | 57 | male | 0 | 12 | 6.8 | 4 | osimertinib 80 mg daily | 22.3 | false | MSI-H | 2026-03-15T05:35:59.391977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552496 | REC_0010188 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.7 | 83 | female | 1 | 7 | 3.8 | 4 | alectinib 600 mg BID | 14.4 | true | MSS | 2026-03-15T05:35:59.392351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157489 | REC_0010189 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.3 | 61 | male | 1 | 15 | 4 | 1 | sotorasib 960 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:59.392626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137689 | REC_0010190 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6 | 60 | male | 0 | 19 | 6.2 | 5 | sotorasib 960 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:59.392884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667000 | REC_0010191 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 7.9 | 64 | female | 1 | 88 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.3 | true | MSS | 2026-03-15T05:35:59.393137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761491 | REC_0010192 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 17.9 | 69 | female | 0 | 16 | 4.6 | 6 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:59.393396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436456 | REC_0010193 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.2 | 67 | male | 0 | 15 | 5.6 | 5 | sotorasib 960 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:59.393767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428884 | REC_0010194 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.8 | 70 | female | 1 | 14 | 8 | 7 | sotorasib 960 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:59.394038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905278 | REC_0010195 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.6 | 56 | female | 1 | 11 | 4.7 | 5 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.394300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412335 | REC_0010196 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 7.6 | 64 | female | 1 | 17 | 5.8 | 7 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:35:59.394550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292261 | REC_0010197 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 15.8 | 78 | male | 2 | 31 | 4.6 | 1 | osimertinib 80 mg daily | 25.5 | true | MSS | 2026-03-15T05:35:59.394802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285759 | REC_0010198 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8 | 64 | male | 1 | 73 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:59.395051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958502 | REC_0010199 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.4 | 64 | male | 1 | 11 | 5.2 | 6 | entrectinib 600 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:59.395297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148471 | REC_0010200 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.6 | 86 | female | 2 | 25 | 5.3 | 4 | osimertinib 80 mg daily | 6 | false | MSI-H | 2026-03-15T05:35:59.395544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.